China launches crackdown on drug industry

July 17, 2013 by Joe Mcdonald

(AP)—China announced a crackdown Wednesday on misconduct in its drug market, stepping up pressure on the problem-prone industry while it pursues a bribery investigation of GlaxoSmithKline.

The six-month crackdown is aimed at stamping out unauthorized drug production, improper online drug retailing and sales of fake traditional Chinese medicines, the State Food and Drug Administration said.

"We must resolutely punish illegal acts, resolutely close illegal enterprises and firmly recall problematic products," a deputy director of the agency, Wu Zhen, said in a statement on its website.

The announcement came two days after Chinese police accused GSK employees of conducting a multimillion-dollar campaign to encourage doctors to prescribe its medications. The statement did not mention the British .

The new Chinese leadership that took power in November has promised to improve China's health system and reining in surging costs of medicine and medical care that are fueling public frustration.

China has suffered repeated scandals over fake or shoddy medications, some of which caused deaths and injuries. Regulators have launched repeated crackdowns on false advertising and other violations, but with limited success.

From July through December, investigators will examine manufacturers, markets, clinics and online stores, the agency said.

The police ministry said this week that GSK employees paid to doctors and officials of hospitals, medical associations and the government to encourage use of its medications.

According to Chinese news reports, police say the employees funneled as much as 3 billion yuan ($490 million) through travel agencies and consulting firms to hide the source of bribes. Police said four employees including a vice president of GSK's China unit have been detained.

The official Xinhua News Agency said the scheme appeared to be aimed at evading GSK's internal controls meant to prevent bribery.

On Tuesday, state television showed one of the detained GSK employees describing how he paid bribes to government officials to win support for use of the company's medications.

Also Wednesday, a Commerce Ministry spokesman warned that misconduct by manufacturers would be punished.

"Whether they are domestic or foreign-invested enterprises, if they violate Chinese law, they will be subject to legal sanctions and bear responsibility," said spokesman Shen Danyang at a news briefing.

Meanwhile, the Cabinet's planning agency is investigating production costs at 60 Chinese and foreign pharmaceutical manufacturers, according to state media, possible as a prelude to revising state-imposed price caps on key medications.

The government also is investigating possible price-fixing by foreign milk suppliers.

Explore further: Chinese police say Glaxo employees bribed doctors

Related Stories

Chinese police say Glaxo employees bribed doctors

July 11, 2013
China's police ministry accused executives of pharmaceutical supplier GlaxoSmithKline on Thursday of conducting a large and long-running bribery campaign to persuade doctors to prescribe drugs.

China government to probe 60 firms over drug prices

July 4, 2013
China's top economic planner is to investigate 60 pharmaceutical companies for excessive charges, including several joint ventures with foreign firms, state media reported Thursday.

Taiwan's Foxconn reviews buying in China after bribe claims

January 9, 2013
Taiwan technology giant Foxconn said Wednesday it was investigating and reviewing its acquisition procedures in China after allegations that some of its managers had solicited bribes from suppliers.

China arrests nearly 2,000 in fake drug crackdown

August 6, 2012
(AP) — China's Ministry of Public Security says it has detained nearly 2,000 people in a nationwide crackdown on counterfeit drugs, including some to treat cancer.

UK alleges GSK paid off competitors to delay drugs

April 19, 2013
Britain's competition watchdog accused GlaxoSmithKline on Friday of paying off competitors to delay launches of their own versions of GSK's best-selling antidepressant, Seroxat.

Recommended for you

Best of Last Year—The top Medical Xpress articles of 2017

December 20, 2017
It was a good year for medical research as a team at the German center for Neurodegenerative Diseases, Magdeburg, found that dancing can reverse the signs of aging in the brain. Any exercise helps, the team found, but dancing ...

Pickled in 'cognac', Chopin's heart gives up its secrets

November 26, 2017
The heart of Frederic Chopin, among the world's most cherished musical virtuosos, may finally have given up the cause of his untimely death.

Sugar industry withheld evidence of sucrose's health effects nearly 50 years ago

November 21, 2017
A U.S. sugar industry trade group appears to have pulled the plug on a study that was producing animal evidence linking sucrose to disease nearly 50 years ago, researchers argue in a paper publishing on November 21 in the ...

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.